438568-89-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-4,5,6,7-tetrahydrobenzo[d]thiazole is used as a building block for the synthesis of various pharmaceutical products. Its unique chemical structure allows for the development of drugs with anti-inflammatory, antibacterial, and analgesic properties. 2-Bromo-4,5,6,7-tetrahydrobenzo[d]thiazole's potential applications in drug development make it a valuable asset in the pharmaceutical industry.
Used in Pesticide and Fungicide Development:
2-Bromo-4,5,6,7-tetrahydrobenzo[d]thiazole has been studied for its potential use as a pesticide and fungicide. Its chemical properties and structure make it a promising candidate for the development of effective and environmentally friendly pest control solutions. 2-Bromo-4,5,6,7-tetrahydrobenzo[d]thiazole's potential applications in agriculture can contribute to the development of safer and more efficient pest management strategies.
Used in Organic Synthesis:
2-Bromo-4,5,6,7-tetrahydrobenzo[d]thiazole's unique structure and properties make it a valuable starting material for the synthesis of diverse organic compounds. 2-Bromo-4,5,6,7-tetrahydrobenzo[d]thiazole can be used in the development of various organic compounds with potential applications in the biomedical and agricultural fields. Its versatility as a building block allows for the creation of new compounds with specific properties and functions, expanding the scope of chemical research and development.

Upstream product

• 144-55-8 sodium hydrogencarbonate 
• 23839-33-0 2-thiocyanatocyclohexanone 
• 2933-29-1 2-Amino-4,5,6,7-tetrahydrobenzothiazole 
• 540-80-7 tert.-butylnitrite 
• 108-94-1 cyclohexanone 
• 1056477-06-5 2-bromocyclohexanone 

Relevant academic research and scientific papers

Quinoxaline compound, preparation method and application of quinoxaline compound in medicine

The invention provides a quinoxaline compound, a preparation method and application of the quinoxaline compound in medicine, and particularly relates to a quinoxaline compound with PAR4 antagonistic activity, a preparation method of the quinoxaline compound, a pharmaceutical composition containing the quinoxaline compound and application of the quinoxaline compound. Specifically, the invention provides a compound shown as a general formula I and/or II or a tautomer or pharmaceutically acceptable salt thereof, a preparation method of the compound, and application of the compound or the tautomer or the pharmaceutically acceptable salt in medicines for preventing and/or treating thromboembolic diseases.

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

Bicyclic heteroaryl compound with PAR4 antagonistic activity and application thereof

The invention discloses a bicyclic heteroaryl compound with PAR4 antagonistic activity and application thereof. The invention provides the bicyclic heteroaryl compound with PAR4 antagonistic activity,and the bicyclic heteroaryl compound has remarkable antagonistic activity on PAR4 in an in-vitro anti-platelet aggregation experiment, so that platelet aggregation is effectively inhibited, and the bicyclic heteroaryl compound can be used for preparing medicines for preventing or treating various thromboembolic diseases.

Azole derivatives as histamine H3 receptor antagonists, Part I: Thiazol-2-yl ethers

Most human histamine H3 receptor (hH3R) antagonists follow a general structural blueprint, containing a basic moiety linked by a spacer to a substituted core element. In this investigation the acceptance of thiazol-2-yl ether moieties in the core region is proved with some ether derivatives showing hH3R binding affinities in the nanomolar concentration range. A diversity of structural motifs is used as substituents to enhance the in vitro hH3R binding affinity.

Condensation reagents and a process for their preparation

The present invention relates to new bromo- and chlorothiazolium salts of the formula (I) in which R1, R2, R3, R4, n and X? have the meaning indicated in the disclosure, a process for their preparation, their use as condensation reagents, particularly as peptide coupling reagents, and intermediates for the preparation of these compounds.